Pheon launches to progress ADCs for solid tumour treatment
The latest funding will aid the company to progress its lead ADC programme to clinical proof-of-concept.
Oncology
Latest in
Oncology
US FDA grants orphan drug status for Verismo’s mesothelioma therapy
Phase I trials of SynKIR-110 in mesothelin-expressing mesothelioma, cholangiocarcinoma and ovarian cancer will begin next year.
Scribe and Sanofi partner to develop cell therapies for cancer
Scribe is entitled to receive potential payments worth over $1bn on meeting development and commercial milestones.
Japan grants approvals for Merck’s Keytruda to treat different cancers
Cervical cancer and melanoma indications are based on results from the KEYNOTE-826 and KEYNOTE-716 trials, respectively.
Seagen and Lava enter licence agreement for solid tumour therapy
Lava will receive an upfront payment of $50m from Seagen for an exclusive worldwide licence to LAVA-1223.
UK NICE grants approval for breast cancer drug combination
A CDK4/6 inhibitor, palbociclib is administered once a day as a pill in breast cancer patients.
Fennec’s hearing loss drug for cancer patients wins breakthrough FDA nod
Pedmark is indicated to treat cisplatin-induced ototoxicity in children and adolescents, the first approval of its kind for this group.
By
Sesen Bio and Carisma enter deal to combine businesses
The Sesen Bio and Carisma boards of directors have granted unanimous approval for the deal.